Full-Time

Principal Scientist

Antibody Drug Conjugates

Confirmed live in the last 24 hours

AbCellera Biologics

AbCellera Biologics

501-1,000 employees

Discovers and develops therapeutic antibodies

AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

CA$141.1k - CA$177kAnnually

+ Equity + Annual Bonus

Expert

Vancouver, BC, Canada

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD in Biochemistry, Biological Chemistry, Chemistry, or a related field, plus 10+ years of industry experience; if you have a MSc and 15+ years of related industry experience, you will also be considered
  • Hands-on experience with and an understanding of laboratory techniques used to generate and evaluate antibody drug conjugates
  • Comprehensive knowledge of modern antibody linker technologies, and working knowledge of antibody structure and function
  • Strong interpersonal skills with the ability to work collaboratively as a member of cross-functional team
  • Excellent verbal and written communication skills, including public presentation of complex data
  • Strongly self-motivated and work independently to identify project needs and follow that up with building and implementing solutions
Responsibilities
  • Providing leadership in the design, optimization, and development of cutting-edge Antibody Drug Conjugate (ADC) therapeutic candidates
  • Providing strategic direction to ADC Discovery programs
  • Designing, implementing, evaluating and optimizing conjugation methods and platforms
  • Leading and inspiring a team of scientists to execute high-impact ADC research
  • Collaborating with teams across the company to understand ADC challenges and propose solutions
  • Driving innovation by exploring and implementing emerging technologies in the field of conjugate science and ADC therapeutic discovery
  • Preparing and authoring materials to educate colleagues, and communicate strategies, key findings and implications
  • Organizing, supporting and collaborating with other team members to meet project deliverables and timelines

AbCellera focuses on discovering and developing therapeutic antibodies for various diseases. The company uses a proprietary technology platform that combines different scientific methods to identify and create antibodies efficiently. Clients, including pharmaceutical companies and research institutions, partner with AbCellera to enhance their drug development processes. Unlike many competitors, AbCellera excels at addressing challenging targets that traditional methods struggle with. The company's goal is to advance new treatments to market while generating revenue through partnerships, discovery services, and its own therapeutic programs.

Company Stage

IPO

Total Funding

$620.9M

Headquarters

Vancouver, Canada

Founded

2012

Growth & Insights
Headcount

6 month growth

3%

1 year growth

5%

2 year growth

25%
Simplify Jobs

Simplify's Take

What believers are saying

  • Collaboration with Biogen could lead to breakthroughs in neurological treatments.
  • Partnership with Eli Lilly expands AbCellera's reach in diverse therapeutic areas.
  • Acquisition of Dualogics' platform strengthens AbCellera's competitive position.

What critics are saying

  • Peter Thiel's resignation may impact strategic guidance and investor confidence.
  • High-risk research with Biogen could lead to delays or failures.
  • Resource allocation challenges may arise from multiple new biotech ventures.

What makes AbCellera Biologics unique

  • AbCellera's platform integrates diverse scientific approaches for efficient antibody discovery.
  • The company excels in tackling challenging targets with innovative methods.
  • AbCellera's strategic partnerships enhance its antibody development capabilities.

Help us improve and share your feedback! Did you find this helpful?